Advertisement

Topics

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

2014-08-27 03:19:38 | BioPortfolio

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.

Description

This is a double-blind, randomized, parallel-group, controlled, repeat dose, single center study to evaluate the efficacy and safety of a repeat application of RT001 compared to placebo gel in at least 36 subjects with moderate to severe lateral canthal lines (LCL). Subjects will be randomized to 1 of 2 treatment groups in a 1:1 ratio (active versus placebo). At least 36 adult volunteers who have provided informed consent and have met the study eligibility criteria will be enrolled. There will be 18 subjects in each treatment group.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Lateral Canthal Lines

Intervention

Botulinum Toxin Type A, Placebo

Location

Dermatology Research Institute, LLC.
Coral Gables
Florida
United States
33146

Status

Completed

Source

Revance Therapeutics, Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:19:38-0400

Clinical Trials [1791 Associated Clinical Trials listed on BioPortfolio]

ET-01 in Subjects With Lateral Canthal Lines

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hair...

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, ...

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

PubMed Articles [12669 Associated PubMed Articles listed on BioPortfolio]

Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.

BACKGROUND Baclofen is approved by the US FDA to treat spasticity, but its sustained use may cause drug addiction. The objective of this study was to compare the efficacy and safety of botulinum toxin...

Review: In trigeminal neuralgia, carbamazepine, botulinum toxin type A, or lidocaine improve response rate vs placebo.

The Potential Role of Botulinum Toxin in Improving Superficial Cutaneous Scarring: A Review.

Botulinum toxins have been utilized in a number of cosmetic and therapeutic applications. One of the more novel uses of botulinum toxin involves its use to mitigate the effects of superficial cutaneou...

Six-Month Comparative Analysis Monitoring the Progression of the Largest Diameter of the Sweating Inhibition Halo of Different Botulinum Toxins Type-A.

Excessive sweating is a clinical condition that can be improved with type-A botulinum toxin (BTX-A).

MR-guided navigation for botulinum toxin injection in the lateral pterygoid muscle. First results in the treatment of temporomandibular joint disorders.

Hyperactivity of the lateral pterygoid muscle (LPM) is one of the presumed mechanisms of the onset of temporomandibular disorders (TMD) and explains why intramuscular injection of botulinum toxin (BT)...

Medical and Biotech [MESH] Definitions

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type G. Though it has been isolated from soil, no outbreaks involving this type have been recognized.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type C which is neurotoxic to ANIMALS, especially CATTLE, but not humans. It causes dissociation of ACTIN FILAMENTS.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type D which is neurotoxic to ANIMALS, especially CATTLE, but not humans.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type B which is neurotoxic to humans and animals.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type E which is neurotoxic to humans and animals.

More From BioPortfolio on "Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial